FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225156771> ?p ?o ?g. }

• W4225156771 endingPage "392" @default.
• W4225156771 startingPage "386" @default.
• W4225156771 abstract "Background SMARCA4-deficient thoracic tumor is a novel disease entity characterized by mutations in SMARCA4 resulting in loss of its expression. They could be divided according to their phenotypes; carcinoma or sarcomatoid. It remains unclear how many patients with these SMARCA4-deficient tumors could benefit from inhibitors of programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1). Methods SMARCA4-deficient thoracic tumor cases were retrospectively identified from pathology and gene expression databases at the National Cancer Center Hospital in Japan. Clinical outcomes of patients treated with PD-1/PD-L1 inhibitors were reviewed. Results Eighteen patients with SMARCA4-deficient thoracic tumor [carcinoma (n = 10), sarcomatoid (n = 7), and ambiguous type (n = 1)] were identified. Of the twelve [carcinoma (n = 7), sarcomatoid (n = 5)] who had received immune checkpoint inhibitors (ICIs), 5 [carcinoma (n = 3), sarcomatoid (n = 2)] showed a partial response, all of whom had received an ICI as the first-line therapy. The overall response rate was The PD-L1 tumor proportion scores of the 5 responding patients were 100%, 80%, 5% (n = 2), and less than 1%. The median progression-free survival (PFS) of all the patients was 2.4 months [95% confidence interval (CI), 1.1 months–not achieved (NA)], while the median PFS of the 3 patients who received first-line ICIs was not reached (95% CI, 1.1 months–NA). Conclusion PD-1/PD-L1 inhibitors showed promising results in the treatment of SMARCA4-deficient tumor. Further studies, especially on patient selection and combination therapy, are needed." @default.
• W4225156771 created "2022-05-01" @default.
• W4225156771 creator A5002845200 @default.
• W4225156771 creator A5005497931 @default.
• W4225156771 creator A5006840327 @default.
• W4225156771 creator A5016850482 @default.
• W4225156771 creator A5029558855 @default.
• W4225156771 creator A5030587345 @default.
• W4225156771 creator A5033956905 @default.
• W4225156771 creator A5064362444 @default.
• W4225156771 creator A5069589468 @default.
• W4225156771 creator A5081785503 @default.
• W4225156771 creator A5090846902 @default.
• W4225156771 date "2022-07-01" @default.
• W4225156771 modified "2023-10-18" @default.
• W4225156771 title "Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor" @default.
• W4225156771 cites W1760824447 @default.
• W4225156771 cites W2019607817 @default.
• W4225156771 cites W2027577263 @default.
• W4225156771 cites W2119079421 @default.
• W4225156771 cites W2128110268 @default.
• W4225156771 cites W2132955371 @default.
• W4225156771 cites W2133647396 @default.
• W4225156771 cites W2215528453 @default.
• W4225156771 cites W2594900560 @default.
• W4225156771 cites W2645317906 @default.
• W4225156771 cites W2779221466 @default.
• W4225156771 cites W2796582438 @default.
• W4225156771 cites W2802645166 @default.
• W4225156771 cites W2805354595 @default.
• W4225156771 cites W2910245285 @default.
• W4225156771 cites W2925446385 @default.
• W4225156771 cites W2940105435 @default.
• W4225156771 cites W2945474619 @default.
• W4225156771 cites W2980545322 @default.
• W4225156771 cites W2983766759 @default.
• W4225156771 cites W3002190870 @default.
• W4225156771 doi "https://doi.org/10.1016/j.cllc.2022.03.005" @default.
• W4225156771 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35618627" @default.
• W4225156771 hasPublicationYear "2022" @default.
• W4225156771 type Work @default.
• W4225156771 citedByCount "6" @default.
• W4225156771 countsByYear W42251567712022 @default.
• W4225156771 countsByYear W42251567712023 @default.
• W4225156771 crossrefType "journal-article" @default.
• W4225156771 hasAuthorship W4225156771A5002845200 @default.
• W4225156771 hasAuthorship W4225156771A5005497931 @default.
• W4225156771 hasAuthorship W4225156771A5006840327 @default.
• W4225156771 hasAuthorship W4225156771A5016850482 @default.
• W4225156771 hasAuthorship W4225156771A5029558855 @default.
• W4225156771 hasAuthorship W4225156771A5030587345 @default.
• W4225156771 hasAuthorship W4225156771A5033956905 @default.
• W4225156771 hasAuthorship W4225156771A5064362444 @default.
• W4225156771 hasAuthorship W4225156771A5069589468 @default.
• W4225156771 hasAuthorship W4225156771A5081785503 @default.
• W4225156771 hasAuthorship W4225156771A5090846902 @default.
• W4225156771 hasConcept C104317684 @default.
• W4225156771 hasConcept C121608353 @default.
• W4225156771 hasConcept C126322002 @default.
• W4225156771 hasConcept C143998085 @default.
• W4225156771 hasConcept C167227067 @default.
• W4225156771 hasConcept C185592680 @default.
• W4225156771 hasConcept C2776256026 @default.
• W4225156771 hasConcept C2776349617 @default.
• W4225156771 hasConcept C2776694085 @default.
• W4225156771 hasConcept C2777546739 @default.
• W4225156771 hasConcept C2780808757 @default.
• W4225156771 hasConcept C55493867 @default.
• W4225156771 hasConcept C71924100 @default.
• W4225156771 hasConcept C80828422 @default.
• W4225156771 hasConcept C83640560 @default.
• W4225156771 hasConceptScore W4225156771C104317684 @default.
• W4225156771 hasConceptScore W4225156771C121608353 @default.
• W4225156771 hasConceptScore W4225156771C126322002 @default.
• W4225156771 hasConceptScore W4225156771C143998085 @default.
• W4225156771 hasConceptScore W4225156771C167227067 @default.
• W4225156771 hasConceptScore W4225156771C185592680 @default.
• W4225156771 hasConceptScore W4225156771C2776256026 @default.
• W4225156771 hasConceptScore W4225156771C2776349617 @default.
• W4225156771 hasConceptScore W4225156771C2776694085 @default.
• W4225156771 hasConceptScore W4225156771C2777546739 @default.
• W4225156771 hasConceptScore W4225156771C2780808757 @default.
• W4225156771 hasConceptScore W4225156771C55493867 @default.
• W4225156771 hasConceptScore W4225156771C71924100 @default.
• W4225156771 hasConceptScore W4225156771C80828422 @default.
• W4225156771 hasConceptScore W4225156771C83640560 @default.
• W4225156771 hasIssue "5" @default.
• W4225156771 hasLocation W42251567711 @default.
• W4225156771 hasLocation W42251567712 @default.
• W4225156771 hasOpenAccess W4225156771 @default.
• W4225156771 hasPrimaryLocation W42251567711 @default.
• W4225156771 hasRelatedWork W2092199274 @default.
• W4225156771 hasRelatedWork W2399407454 @default.
• W4225156771 hasRelatedWork W2417805311 @default.
• W4225156771 hasRelatedWork W25275382 @default.
• W4225156771 hasRelatedWork W2555847059 @default.
• W4225156771 hasRelatedWork W3016766734 @default.
• W4225156771 hasRelatedWork W3027936046 @default.

• next